Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 61/775,060, filed Mar 8, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,650,412 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances In force · High confidence UsedRemaining | Genzyme Corporation | In force | High confidence | ||
| US 9,650,413 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances In force · Medium confidence | Genzyme Corporation | In force | Medium confidence | ||
| US 9,657,056 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| US 10,711,034 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances In force · Low confidence | Genzyme Corporation | In force | Low confidence | ||
| US 12,110,312 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances In force · Low confidence | Genzyme Corporation | In force | Low confidence | ||
| Application 18/817,164 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances Pending Not granted | Genzyme Corporation | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Genzyme Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.